A Randomized Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) Administered Intravenously to Subjects With Atopic Dermatitis (AD)

Trial Profile

A Randomized Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) Administered Intravenously to Subjects With Atopic Dermatitis (AD)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2018

At a glance

  • Drugs Fezakinumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2018 New trial record
    • 15 Jan 2018 Primary endpoint (To assess the clinical benefit as measured by SCORAD (Scoring of AD) of intravenous (IV) administration of ILV-094 administered to subjects with atopic dermatitis (AD) has not been met, according to results published in the Journal of the American Academy of Dermatology.
    • 15 Jan 2018 Results published in the Journal of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top